<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422058</url>
  </required_header>
  <id_info>
    <org_study_id>NN8022-1807</org_study_id>
    <secondary_id>2006-004481-13</secondary_id>
    <nct_id>NCT00422058</nct_id>
    <nct_alias>NCT00480909</nct_alias>
  </id_info>
  <brief_title>The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes</brief_title>
  <official_title>Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the
      efficacy of liraglutide to induce body weight loss and the purpose of the extension is to
      evaluate the long term safety and tolerability of liraglutide.

      Trial has the following trial periods: A 20-week randomised, double-blind,
      placebo-controlled, six-armed parallel-group, multi-centre, multinational trial with an open
      label orlistat comparator arm followed by an 84 week extension period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2007</start_date>
  <completion_date type="Actual">April 30, 2009</completion_date>
  <primary_completion_date type="Actual">September 13, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Body Weight at Week 20</measure>
    <time_frame>Week 0, week 20</time_frame>
    <description>Calculated as mean body weight at week 20 - baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Body Weight at Week 104</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Calculated as mean body weight at week 104 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Week 20</measure>
    <time_frame>Week 0, week 20</time_frame>
    <description>Calculated as mean fasting plasma glucose at week 20 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Week 104</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Calculated as mean fasting plasma glucose at week 104 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Insulin at Week 20</measure>
    <time_frame>Week 0, week 20</time_frame>
    <description>Calculated as mean fasting insulin at week 20 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Insulin at Week 104</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Calculated as mean fasting insulin at week 104 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 20</measure>
    <time_frame>Week 0, week 20</time_frame>
    <description>Calculated as mean HbA1c (glycosylated haemoglobin A1c) at week 20 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 104</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Calculated as mean HbA1c (glycosylated haemoglobin A1c) at week 104 - baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP (Highly Sensitive C-reactive Protein) at Week 20</measure>
    <time_frame>Week 0, week 20</time_frame>
    <description>Calculated as mean hsCRP (highly sensitive C-reactive protein) at week 20-baseline. High hsCRP level is associated with greater cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP (Highly Sensitive C-reactive Protein) at Week 104</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Calculated as mean hsCRP (highly sensitive C-reactive protein) at week 104- baseline. High hsCRP level is associated with greater cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PAI-1 (Plasminogen Activator Inhibitor 1) at Week 20</measure>
    <time_frame>Week 0, week 20</time_frame>
    <description>Calculated as mean PAI-1 (plasminogen activator inhibitor 1) at week 20-baseline. High PAI-1 is associated with greater cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PAI-1 (Plasminogen Activator Inhibitor 1) at Week 104</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Calculated as mean PAI-1 (plasminogen activator inhibitor 1) at week 104-baseline. High PAI-1 is associated with greater cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fibrinogen at Week 20</measure>
    <time_frame>Week 0, week 20</time_frame>
    <description>Calculated as mean fibrinogen at week 20 - baseline. High fibrinogen is associated with greater cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fibrinogen at Week 104</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Calculated as mean fibrinogen at week 104 - baseline. High fibrinogen is associated with greater cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adiponectin at Week 20</measure>
    <time_frame>Week 0, week 20</time_frame>
    <description>Calculated as mean adiponectin at week 20-baseline. A low adiponectin level is associated with greater cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adiponectin at Week 104</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Calculated as mean adiponectin at week 104-baseline. A low adiponectin level is associated with greater cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference at Week 20</measure>
    <time_frame>Week 0, week 20</time_frame>
    <description>Calculated as mean waist circumference at week 20-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference at Week 104</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Calculated as mean waist circumference at week 104-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure at Week 20</measure>
    <time_frame>Week 0, week 20</time_frame>
    <description>Calculated as mean blood pressure at week 20-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure at Week 104</measure>
    <time_frame>Week 0, week 104</time_frame>
    <description>Calculated as mean blood pressure at week 104-baseline.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">564</enrollment>
  <condition>Metabolism and Nutrition Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lira placebo/Lira 2.4 mg/Lira 3.0 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lira 1.2 mg/Lira 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lira 1.8 mg/Lira 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lira 2.4 mg/Lira 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orlistat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Injected s.c. (under the skin) once daily</description>
    <arm_group_label>Lira 1.2 mg/Lira 3.0 mg</arm_group_label>
    <arm_group_label>Lira 1.8 mg/Lira 3.0 mg</arm_group_label>
    <arm_group_label>Lira 2.4 mg/Lira 3.0 mg</arm_group_label>
    <arm_group_label>Liraglutide 3.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>orlistat</intervention_name>
    <description>120 mg capsule. Administered thrice daily</description>
    <arm_group_label>Orlistat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Injected s.c. (under the skin) once daily</description>
    <arm_group_label>Lira placebo/Lira 2.4 mg/Lira 3.0 mg</arm_group_label>
    <arm_group_label>Liraglutide 3.0 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) greater than or equal to 30.0 or lesser than or equal to 40.0
             kg/m2

          -  Stable body weight (less than 5% selfreported change within the last 3 months)

        Exclusion Criteria:

          -  Obesity induced by drug treatment

          -  Use of approved drugs for weight lowering intervention (e.g. orlistat, sibutramin,
             rimonabant) within the last 3 months prior to entering trial

          -  Type 1 or type 2 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Praha 1</city>
        <zip>116 94</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Frederiksberg C</city>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Århus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00270</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Almere</city>
        <zip>1311RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G322ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Luton</city>
        <zip>LU4 0DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L; NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012 Jun;36(6):843-54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Erratum in: Int J Obes (Lond). 2012 Jun;36(6):890. Int J Obes (Lond). 2013 Feb;37(2):322.</citation>
    <PMID>21844879</PMID>
  </results_reference>
  <results_reference>
    <citation>Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009 Nov 7;374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1. Epub 2009 Oct 23. Erratum in: Lancet. 2010 Mar 20;375(9719):984.</citation>
    <PMID>19853906</PMID>
  </results_reference>
  <results_reference>
    <citation>Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, Van Gaal L, Astrup A; NN8022-1807 Investigators. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond). 2014 May;38(5):689-97. doi: 10.1038/ijo.2013.149. Epub 2013 Aug 14.</citation>
    <PMID>23942319</PMID>
  </results_reference>
  <results_reference>
    <citation>Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Diabetes Care. 2017 Jul;40(7):839-848. doi: 10.2337/dc16-2684. Epub 2017 May 4.</citation>
    <PMID>28473337</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, Brett J, Cancino AP, Wilding JPH; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 Nov;19(11):1529-1536. doi: 10.1111/dom.12963. Epub 2017 Jul 21.</citation>
    <PMID>28386912</PMID>
  </results_reference>
  <results_reference>
    <citation>Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018 Mar;20(3):734-739. doi: 10.1111/dom.13125. Epub 2017 Nov 1.</citation>
    <PMID>28950422</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2007</study_first_posted>
  <results_first_submitted>April 27, 2010</results_first_submitted>
  <results_first_submitted_qc>October 5, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2010</results_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>19 sites in 8 countries: Denmark (3), Sweden (2), Finland (3), UK (3), Netherlands (1), Belgium (1), Spain (4) and Czech Republic (2)</recruitment_details>
      <pre_assignment_details>Between screening and randomisation, eligible subjects were included in a 2-week single-blind run-in period in which all subjects were placed on a hypocaloric diet. The dose of liraglutide and placebo was increased during the first 4 weeks after randomisation until maintenance dose was reached. Orlistat dose was fixed from randomisation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
          <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="P2">
          <title>Lira 1.2 mg/Lira 3.0 mg</title>
          <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="P3">
          <title>Lira 1.8 mg/Lira 3.0 mg</title>
          <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="P4">
          <title>Lira 2.4 mg/Lira 3.0 mg</title>
          <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="P5">
          <title>Liraglutide 3.0 mg</title>
          <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="P6">
          <title>Orlistat</title>
          <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind, Week 0-20</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="93"/>
                <participants group_id="P5" count="93"/>
                <participants group_id="P6" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="73"/>
                <participants group_id="P5" count="82"/>
                <participants group_id="P6" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Extension, Week 20-104</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="73"/>
                <participants group_id="P5" count="82"/>
                <participants group_id="P6" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled in Extension</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="65"/>
                <participants group_id="P5" count="72"/>
                <participants group_id="P6" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="35"/>
                <participants group_id="P6" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not giving consent for extension</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
          <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="B2">
          <title>Lira 1.2 mg/Lira 3.0 mg</title>
          <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="B3">
          <title>Lira 1.8 mg/Lira 3.0 mg</title>
          <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="B4">
          <title>Lira 2.4 mg/Lira 3.0 mg</title>
          <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="B5">
          <title>Liraglutide 3.0 mg</title>
          <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="B6">
          <title>Orlistat</title>
          <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="90"/>
            <count group_id="B4" value="93"/>
            <count group_id="B5" value="93"/>
            <count group_id="B6" value="95"/>
            <count group_id="B7" value="564"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.86" spread="10.28"/>
                    <measurement group_id="B2" value="47.18" spread="9.72"/>
                    <measurement group_id="B3" value="45.53" spread="10.9"/>
                    <measurement group_id="B4" value="45.01" spread="11.09"/>
                    <measurement group_id="B5" value="45.91" spread="10.71"/>
                    <measurement group_id="B6" value="45.94" spread="9.11"/>
                    <measurement group_id="B7" value="45.91" spread="10.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="70"/>
                    <measurement group_id="B6" value="73"/>
                    <measurement group_id="B7" value="429"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="92"/>
                    <measurement group_id="B6" value="93"/>
                    <measurement group_id="B7" value="555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>BMI = Body Mass Index</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.9" spread="2.8"/>
                    <measurement group_id="B2" value="34.8" spread="2.6"/>
                    <measurement group_id="B3" value="35.0" spread="2.6"/>
                    <measurement group_id="B4" value="35.0" spread="2.8"/>
                    <measurement group_id="B5" value="34.8" spread="2.8"/>
                    <measurement group_id="B6" value="34.1" spread="2.6"/>
                    <measurement group_id="B7" value="34.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.3" spread="12.3"/>
                    <measurement group_id="B2" value="96.2" spread="13.5"/>
                    <measurement group_id="B3" value="98.0" spread="12.5"/>
                    <measurement group_id="B4" value="98.4" spread="13.0"/>
                    <measurement group_id="B5" value="97.6" spread="13.7"/>
                    <measurement group_id="B6" value="96.0" spread="11.7"/>
                    <measurement group_id="B7" value="97.2" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.3" spread="10.0"/>
                    <measurement group_id="B2" value="108.8" spread="10.4"/>
                    <measurement group_id="B3" value="108.2" spread="9.5"/>
                    <measurement group_id="B4" value="110.2" spread="10.7"/>
                    <measurement group_id="B5" value="108.9" spread="8.3"/>
                    <measurement group_id="B6" value="107.6" spread="9.7"/>
                    <measurement group_id="B7" value="108.7" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <description>HbA1c = glycosylated haemoglobin A1c</description>
          <units>percentage (%) of total haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.60" spread="0.38"/>
                    <measurement group_id="B2" value="5.58" spread="0.33"/>
                    <measurement group_id="B3" value="5.60" spread="0.40"/>
                    <measurement group_id="B4" value="5.54" spread="0.33"/>
                    <measurement group_id="B5" value="5.57" spread="0.40"/>
                    <measurement group_id="B6" value="5.55" spread="0.32"/>
                    <measurement group_id="B7" value="5.60" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123.6" spread="11.1"/>
                    <measurement group_id="B2" value="127.0" spread="13.1"/>
                    <measurement group_id="B3" value="123.4" spread="13.0"/>
                    <measurement group_id="B4" value="126.2" spread="13.9"/>
                    <measurement group_id="B5" value="124.3" spread="11.3"/>
                    <measurement group_id="B6" value="122.7" spread="13.5"/>
                    <measurement group_id="B7" value="124.5" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.8" spread="8.5"/>
                    <measurement group_id="B2" value="79.7" spread="9.1"/>
                    <measurement group_id="B3" value="77.9" spread="7.9"/>
                    <measurement group_id="B4" value="78.6" spread="8.2"/>
                    <measurement group_id="B5" value="77.8" spread="8.3"/>
                    <measurement group_id="B6" value="76.9" spread="7.9"/>
                    <measurement group_id="B7" value="77.9" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Body Weight at Week 20</title>
        <description>Calculated as mean body weight at week 20 - baseline</description>
        <time_frame>Week 0, week 20</time_frame>
        <population>ITT (intention to treat) analysis set using LOCF (last observation carried forward) is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Body Weight at Week 20</title>
          <description>Calculated as mean body weight at week 20 - baseline</description>
          <population>ITT (intention to treat) analysis set using LOCF (last observation carried forward) is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" spread="12.3"/>
                    <measurement group_id="O2" value="96.4" spread="13.4"/>
                    <measurement group_id="O3" value="98.0" spread="12.5"/>
                    <measurement group_id="O4" value="98.4" spread="13.1"/>
                    <measurement group_id="O5" value="97.5" spread="13.8"/>
                    <measurement group_id="O6" value="96.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="3.3"/>
                    <measurement group_id="O2" value="-5.1" spread="3.5"/>
                    <measurement group_id="O3" value="-5.9" spread="5.0"/>
                    <measurement group_id="O4" value="-6.6" spread="4.6"/>
                    <measurement group_id="O5" value="-7.6" spread="4.6"/>
                    <measurement group_id="O6" value="-4.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Body Weight at Week 104</title>
        <description>Calculated as mean body weight at week 104 - baseline</description>
        <time_frame>Week 0, week 104</time_frame>
        <population>ITT (intention to treat) analysis set using LOCF (last observation carried forward) is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Body Weight at Week 104</title>
          <description>Calculated as mean body weight at week 104 - baseline</description>
          <population>ITT (intention to treat) analysis set using LOCF (last observation carried forward) is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" spread="12.3"/>
                    <measurement group_id="O2" value="96.4" spread="13.4"/>
                    <measurement group_id="O3" value="98.0" spread="12.5"/>
                    <measurement group_id="O4" value="98.4" spread="13.1"/>
                    <measurement group_id="O5" value="97.5" spread="13.8"/>
                    <measurement group_id="O6" value="96.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="5.9"/>
                    <measurement group_id="O2" value="-4.9" spread="5.8"/>
                    <measurement group_id="O3" value="-5.6" spread="6.5"/>
                    <measurement group_id="O4" value="-6.4" spread="7.2"/>
                    <measurement group_id="O5" value="-8.2" spread="7.1"/>
                    <measurement group_id="O6" value="-3.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Week 20</title>
        <description>Calculated as mean fasting plasma glucose at week 20 - baseline</description>
        <time_frame>Week 0, week 20</time_frame>
        <population>ITT (intention to treat) analysis set using (LOCF) last observation carried forward is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Week 20</title>
          <description>Calculated as mean fasting plasma glucose at week 20 - baseline</description>
          <population>ITT (intention to treat) analysis set using (LOCF) last observation carried forward is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.42" spread="0.81"/>
                    <measurement group_id="O2" value="5.30" spread="0.61"/>
                    <measurement group_id="O3" value="5.29" spread="0.56"/>
                    <measurement group_id="O4" value="5.27" spread="0.57"/>
                    <measurement group_id="O5" value="5.36" spread="0.61"/>
                    <measurement group_id="O6" value="5.3" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.54"/>
                    <measurement group_id="O2" value="-0.39" spread="0.45"/>
                    <measurement group_id="O3" value="-0.44" spread="0.63"/>
                    <measurement group_id="O4" value="-0.38" spread="0.48"/>
                    <measurement group_id="O5" value="-0.44" spread="0.44"/>
                    <measurement group_id="O6" value="-0.10" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Week 104</title>
        <description>Calculated as mean fasting plasma glucose at week 104 - baseline</description>
        <time_frame>Week 0, week 104</time_frame>
        <population>ITT (intention to treat) analysis set using (LOCF) last observation carried forward is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Week 104</title>
          <description>Calculated as mean fasting plasma glucose at week 104 - baseline</description>
          <population>ITT (intention to treat) analysis set using (LOCF) last observation carried forward is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="86"/>
                <count group_id="O6" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.42" spread="0.81"/>
                    <measurement group_id="O2" value="5.30" spread="0.61"/>
                    <measurement group_id="O3" value="5.29" spread="0.56"/>
                    <measurement group_id="O4" value="5.27" spread="0.57"/>
                    <measurement group_id="O5" value="5.36" spread="0.61"/>
                    <measurement group_id="O6" value="5.30" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.61"/>
                    <measurement group_id="O2" value="-0.09" spread="0.53"/>
                    <measurement group_id="O3" value="-0.09" spread="0.64"/>
                    <measurement group_id="O4" value="-0.20" spread="0.50"/>
                    <measurement group_id="O5" value="-0.23" spread="0.50"/>
                    <measurement group_id="O6" value="0.02" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Insulin at Week 20</title>
        <description>Calculated as mean fasting insulin at week 20 - baseline</description>
        <time_frame>Week 0, week 20</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Insulin at Week 20</title>
          <description>Calculated as mean fasting insulin at week 20 - baseline</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="81"/>
                <count group_id="O6" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" spread="129.2"/>
                    <measurement group_id="O2" value="82.9" spread="43.0"/>
                    <measurement group_id="O3" value="85.7" spread="49.5"/>
                    <measurement group_id="O4" value="88.7" spread="43.3"/>
                    <measurement group_id="O5" value="89.1" spread="51.9"/>
                    <measurement group_id="O6" value="85.5" spread="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.0" spread="34.0"/>
                    <measurement group_id="O2" value="8.7" spread="105.3"/>
                    <measurement group_id="O3" value="-0.7" spread="48.2"/>
                    <measurement group_id="O4" value="-3.9" spread="53.2"/>
                    <measurement group_id="O5" value="-12.3" spread="43.3"/>
                    <measurement group_id="O6" value="-16.7" spread="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Insulin at Week 104</title>
        <description>Calculated as mean fasting insulin at week 104 - baseline</description>
        <time_frame>Week 0, week 104</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Insulin at Week 104</title>
          <description>Calculated as mean fasting insulin at week 104 - baseline</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" spread="129.2"/>
                    <measurement group_id="O2" value="82.9" spread="43.0"/>
                    <measurement group_id="O3" value="85.7" spread="49.5"/>
                    <measurement group_id="O4" value="88.7" spread="43.3"/>
                    <measurement group_id="O5" value="89.1" spread="51.9"/>
                    <measurement group_id="O6" value="85.5" spread="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="53.6"/>
                    <measurement group_id="O2" value="-13.5" spread="39.7"/>
                    <measurement group_id="O3" value="18.6" spread="102.6"/>
                    <measurement group_id="O4" value="-2.1" spread="47.3"/>
                    <measurement group_id="O5" value="-19.6" spread="44.3"/>
                    <measurement group_id="O6" value="-15.3" spread="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 20</title>
        <description>Calculated as mean HbA1c (glycosylated haemoglobin A1c) at week 20 - baseline</description>
        <time_frame>Week 0, week 20</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 20</title>
          <description>Calculated as mean HbA1c (glycosylated haemoglobin A1c) at week 20 - baseline</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>percentage (%) of total haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="79"/>
                <count group_id="O6" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.60" spread="0.38"/>
                    <measurement group_id="O2" value="5.58" spread="0.33"/>
                    <measurement group_id="O3" value="5.60" spread="0.40"/>
                    <measurement group_id="O4" value="5.54" spread="0.34"/>
                    <measurement group_id="O5" value="5.57" spread="0.40"/>
                    <measurement group_id="O6" value="5.55" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.22"/>
                    <measurement group_id="O2" value="-0.14" spread="0.21"/>
                    <measurement group_id="O3" value="-0.21" spread="0.25"/>
                    <measurement group_id="O4" value="-0.22" spread="0.25"/>
                    <measurement group_id="O5" value="-0.24" spread="0.29"/>
                    <measurement group_id="O6" value="0.00" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 104</title>
        <description>Calculated as mean HbA1c (glycosylated haemoglobin A1c) at week 104 - baseline</description>
        <time_frame>Week 0, week 104</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 104</title>
          <description>Calculated as mean HbA1c (glycosylated haemoglobin A1c) at week 104 - baseline</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>percentage (%) of total haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.60" spread="0.38"/>
                    <measurement group_id="O2" value="5.58" spread="0.33"/>
                    <measurement group_id="O3" value="5.60" spread="0.40"/>
                    <measurement group_id="O4" value="5.54" spread="0.34"/>
                    <measurement group_id="O5" value="5.57" spread="0.40"/>
                    <measurement group_id="O6" value="5.55" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.32"/>
                    <measurement group_id="O2" value="-0.25" spread="0.26"/>
                    <measurement group_id="O3" value="-0.30" spread="0.22"/>
                    <measurement group_id="O4" value="-0.25" spread="0.30"/>
                    <measurement group_id="O5" value="-0.35" spread="0.32"/>
                    <measurement group_id="O6" value="-0.18" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP (Highly Sensitive C-reactive Protein) at Week 20</title>
        <description>Calculated as mean hsCRP (highly sensitive C-reactive protein) at week 20-baseline. High hsCRP level is associated with greater cardiovascular risk</description>
        <time_frame>Week 0, week 20</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP (Highly Sensitive C-reactive Protein) at Week 20</title>
          <description>Calculated as mean hsCRP (highly sensitive C-reactive protein) at week 20-baseline. High hsCRP level is associated with greater cardiovascular risk</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="79"/>
                <count group_id="O6" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="4.2"/>
                    <measurement group_id="O2" value="5.1" spread="6.1"/>
                    <measurement group_id="O3" value="4.4" spread="4.5"/>
                    <measurement group_id="O4" value="4.0" spread="4.2"/>
                    <measurement group_id="O5" value="3.8" spread="7.4"/>
                    <measurement group_id="O6" value="4.6" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="4.0"/>
                    <measurement group_id="O2" value="0.1" spread="8.1"/>
                    <measurement group_id="O3" value="-0.8" spread="2.9"/>
                    <measurement group_id="O4" value="0.5" spread="4.7"/>
                    <measurement group_id="O5" value="-1.1" spread="7.2"/>
                    <measurement group_id="O6" value="-0.3" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP (Highly Sensitive C-reactive Protein) at Week 104</title>
        <description>Calculated as mean hsCRP (highly sensitive C-reactive protein) at week 104- baseline. High hsCRP level is associated with greater cardiovascular risk</description>
        <time_frame>Week 0, week 104</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP (Highly Sensitive C-reactive Protein) at Week 104</title>
          <description>Calculated as mean hsCRP (highly sensitive C-reactive protein) at week 104- baseline. High hsCRP level is associated with greater cardiovascular risk</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="4.2"/>
                    <measurement group_id="O2" value="5.1" spread="6.1"/>
                    <measurement group_id="O3" value="4.4" spread="4.5"/>
                    <measurement group_id="O4" value="4.0" spread="4.2"/>
                    <measurement group_id="O5" value="3.8" spread="7.4"/>
                    <measurement group_id="O6" value="4.6" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.6"/>
                    <measurement group_id="O2" value="-1.6" spread="6.0"/>
                    <measurement group_id="O3" value="-0.6" spread="8.6"/>
                    <measurement group_id="O4" value="-0.9" spread="3.2"/>
                    <measurement group_id="O5" value="-2.1" spread="9.3"/>
                    <measurement group_id="O6" value="2.4" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PAI-1 (Plasminogen Activator Inhibitor 1) at Week 20</title>
        <description>Calculated as mean PAI-1 (plasminogen activator inhibitor 1) at week 20-baseline. High PAI-1 is associated with greater cardiovascular risk</description>
        <time_frame>Week 0, week 20</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PAI-1 (Plasminogen Activator Inhibitor 1) at Week 20</title>
          <description>Calculated as mean PAI-1 (plasminogen activator inhibitor 1) at week 20-baseline. High PAI-1 is associated with greater cardiovascular risk</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>U/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="72"/>
                <count group_id="O6" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="9.3"/>
                    <measurement group_id="O2" value="19.5" spread="9.9"/>
                    <measurement group_id="O3" value="19.7" spread="9.8"/>
                    <measurement group_id="O4" value="17.6" spread="8.7"/>
                    <measurement group_id="O5" value="19.0" spread="9.1"/>
                    <measurement group_id="O6" value="17.4" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="8.0"/>
                    <measurement group_id="O2" value="-2.0" spread="7.8"/>
                    <measurement group_id="O3" value="-3.5" spread="9.5"/>
                    <measurement group_id="O4" value="-2.3" spread="9.5"/>
                    <measurement group_id="O5" value="-4.5" spread="8.5"/>
                    <measurement group_id="O6" value="-1.2" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PAI-1 (Plasminogen Activator Inhibitor 1) at Week 104</title>
        <description>Calculated as mean PAI-1 (plasminogen activator inhibitor 1) at week 104-baseline. High PAI-1 is associated with greater cardiovascular risk</description>
        <time_frame>Week 0, week 104</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PAI-1 (Plasminogen Activator Inhibitor 1) at Week 104</title>
          <description>Calculated as mean PAI-1 (plasminogen activator inhibitor 1) at week 104-baseline. High PAI-1 is associated with greater cardiovascular risk</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>U/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="9.3"/>
                    <measurement group_id="O2" value="19.5" spread="9.9"/>
                    <measurement group_id="O3" value="19.7" spread="9.8"/>
                    <measurement group_id="O4" value="17.6" spread="8.7"/>
                    <measurement group_id="O5" value="19.0" spread="9.1"/>
                    <measurement group_id="O6" value="17.4" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="7.0"/>
                    <measurement group_id="O2" value="-0.3" spread="9.1"/>
                    <measurement group_id="O3" value="-0.8" spread="9.8"/>
                    <measurement group_id="O4" value="0.3" spread="9.9"/>
                    <measurement group_id="O5" value="0.4" spread="10.9"/>
                    <measurement group_id="O6" value="2.9" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fibrinogen at Week 20</title>
        <description>Calculated as mean fibrinogen at week 20 - baseline. High fibrinogen is associated with greater cardiovascular risk</description>
        <time_frame>Week 0, week 20</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fibrinogen at Week 20</title>
          <description>Calculated as mean fibrinogen at week 20 - baseline. High fibrinogen is associated with greater cardiovascular risk</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="73"/>
                <count group_id="O6" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="0.67"/>
                    <measurement group_id="O2" value="3.67" spread="0.76"/>
                    <measurement group_id="O3" value="3.75" spread="0.72"/>
                    <measurement group_id="O4" value="3.64" spread="0.72"/>
                    <measurement group_id="O5" value="3.61" spread="0.68"/>
                    <measurement group_id="O6" value="3.68" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.58"/>
                    <measurement group_id="O2" value="0.01" spread="0.50"/>
                    <measurement group_id="O3" value="0.02" spread="0.61"/>
                    <measurement group_id="O4" value="0.10" spread="0.69"/>
                    <measurement group_id="O5" value="0.05" spread="0.55"/>
                    <measurement group_id="O6" value="-0.12" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fibrinogen at Week 104</title>
        <description>Calculated as mean fibrinogen at week 104 - baseline. High fibrinogen is associated with greater cardiovascular risk</description>
        <time_frame>Week 0, week 104</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fibrinogen at Week 104</title>
          <description>Calculated as mean fibrinogen at week 104 - baseline. High fibrinogen is associated with greater cardiovascular risk</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="0.67"/>
                    <measurement group_id="O2" value="3.67" spread="0.76"/>
                    <measurement group_id="O3" value="3.75" spread="0.72"/>
                    <measurement group_id="O4" value="3.64" spread="0.72"/>
                    <measurement group_id="O5" value="3.61" spread="0.68"/>
                    <measurement group_id="O6" value="3.68" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.74"/>
                    <measurement group_id="O2" value="-0.14" spread="0.73"/>
                    <measurement group_id="O3" value="-0.15" spread="0.98"/>
                    <measurement group_id="O4" value="-0.24" spread="0.74"/>
                    <measurement group_id="O5" value="-0.22" spread="0.82"/>
                    <measurement group_id="O6" value="-0.39" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adiponectin at Week 20</title>
        <description>Calculated as mean adiponectin at week 20-baseline. A low adiponectin level is associated with greater cardiovascular risk</description>
        <time_frame>Week 0, week 20</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adiponectin at Week 20</title>
          <description>Calculated as mean adiponectin at week 20-baseline. A low adiponectin level is associated with greater cardiovascular risk</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="79"/>
                <count group_id="O6" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="3.8"/>
                    <measurement group_id="O2" value="5.8" spread="3.8"/>
                    <measurement group_id="O3" value="6.7" spread="4.6"/>
                    <measurement group_id="O4" value="6.2" spread="4.6"/>
                    <measurement group_id="O5" value="6.1" spread="4.0"/>
                    <measurement group_id="O6" value="5.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="5.0"/>
                    <measurement group_id="O2" value="1.2" spread="5.0"/>
                    <measurement group_id="O3" value="1.7" spread="6.9"/>
                    <measurement group_id="O4" value="1.6" spread="5.7"/>
                    <measurement group_id="O5" value="2.3" spread="4.6"/>
                    <measurement group_id="O6" value="1.7" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adiponectin at Week 104</title>
        <description>Calculated as mean adiponectin at week 104-baseline. A low adiponectin level is associated with greater cardiovascular risk</description>
        <time_frame>Week 0, week 104</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adiponectin at Week 104</title>
          <description>Calculated as mean adiponectin at week 104-baseline. A low adiponectin level is associated with greater cardiovascular risk</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="3.8"/>
                    <measurement group_id="O2" value="5.8" spread="3.8"/>
                    <measurement group_id="O3" value="6.7" spread="4.6"/>
                    <measurement group_id="O4" value="6.2" spread="4.6"/>
                    <measurement group_id="O5" value="6.1" spread="4.0"/>
                    <measurement group_id="O6" value="5.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="4.4"/>
                    <measurement group_id="O2" value="3.3" spread="3.8"/>
                    <measurement group_id="O3" value="1.3" spread="3.9"/>
                    <measurement group_id="O4" value="3.4" spread="5.4"/>
                    <measurement group_id="O5" value="3.2" spread="4.1"/>
                    <measurement group_id="O6" value="3.1" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference at Week 20</title>
        <description>Calculated as mean waist circumference at week 20-baseline.</description>
        <time_frame>Week 0, week 20</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist Circumference at Week 20</title>
          <description>Calculated as mean waist circumference at week 20-baseline.</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="85"/>
                <count group_id="O6" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.3" spread="10.0"/>
                    <measurement group_id="O2" value="109.0" spread="10.3"/>
                    <measurement group_id="O3" value="108.2" spread="9.5"/>
                    <measurement group_id="O4" value="110.4" spread="10.6"/>
                    <measurement group_id="O5" value="108.7" spread="8.3"/>
                    <measurement group_id="O6" value="107.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="4.7"/>
                    <measurement group_id="O2" value="-5.8" spread="6.1"/>
                    <measurement group_id="O3" value="-5.9" spread="5.3"/>
                    <measurement group_id="O4" value="-7.2" spread="5.8"/>
                    <measurement group_id="O5" value="-7.9" spread="5.5"/>
                    <measurement group_id="O6" value="-6.0" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference at Week 104</title>
        <description>Calculated as mean waist circumference at week 104-baseline.</description>
        <time_frame>Week 0, week 104</time_frame>
        <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist Circumference at Week 104</title>
          <description>Calculated as mean waist circumference at week 104-baseline.</description>
          <population>ITT (intention to treat) analysis set, only subjects with a valid assessment (LOCF, last observation carried forward not applied).</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.3" spread="10.0"/>
                    <measurement group_id="O2" value="109.0" spread="10.3"/>
                    <measurement group_id="O3" value="108.2" spread="9.5"/>
                    <measurement group_id="O4" value="110.4" spread="10.6"/>
                    <measurement group_id="O5" value="108.7" spread="8.3"/>
                    <measurement group_id="O6" value="107.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="7.2"/>
                    <measurement group_id="O2" value="-8.6" spread="7.5"/>
                    <measurement group_id="O3" value="-9.0" spread="8.7"/>
                    <measurement group_id="O4" value="-10.4" spread="7.8"/>
                    <measurement group_id="O5" value="-9.8" spread="7.5"/>
                    <measurement group_id="O6" value="-9.5" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure at Week 20</title>
        <description>Calculated as mean blood pressure at week 20-baseline.</description>
        <time_frame>Week 0, week 20</time_frame>
        <population>ITT (intention to treat) analysis set using (LOCF) last observation carried forward is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure at Week 20</title>
          <description>Calculated as mean blood pressure at week 20-baseline.</description>
          <population>ITT (intention to treat) analysis set using (LOCF) last observation carried forward is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Systolic )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.6" spread="11.1"/>
                    <measurement group_id="O2" value="127.2" spread="13.1"/>
                    <measurement group_id="O3" value="123.4" spread="13.0"/>
                    <measurement group_id="O4" value="126.3" spread="13.9"/>
                    <measurement group_id="O5" value="124.3" spread="11.3"/>
                    <measurement group_id="O6" value="122.7" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20 (Systolic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="13.3"/>
                    <measurement group_id="O2" value="-6.1" spread="11.1"/>
                    <measurement group_id="O3" value="-4.8" spread="12.7"/>
                    <measurement group_id="O4" value="-9.1" spread="12.3"/>
                    <measurement group_id="O5" value="-6.4" spread="10.0"/>
                    <measurement group_id="O6" value="-4.3" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Diastolic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.78" spread="8.50"/>
                    <measurement group_id="O2" value="79.71" spread="9.12"/>
                    <measurement group_id="O3" value="77.91" spread="7.92"/>
                    <measurement group_id="O4" value="78.53" spread="8.23"/>
                    <measurement group_id="O5" value="77.84" spread="8.38"/>
                    <measurement group_id="O6" value="76.94" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20 (Diastolic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="7.52"/>
                    <measurement group_id="O2" value="-1.53" spread="9.15"/>
                    <measurement group_id="O3" value="-1.61" spread="8.04"/>
                    <measurement group_id="O4" value="-1.39" spread="7.79"/>
                    <measurement group_id="O5" value="-2.37" spread="7.71"/>
                    <measurement group_id="O6" value="-1.96" spread="7.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure at Week 104</title>
        <description>Calculated as mean blood pressure at week 104-baseline.</description>
        <time_frame>Week 0, week 104</time_frame>
        <population>ITT (intention to treat) analysis set using (LOCF) last observation carried forward is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product</population>
        <group_list>
          <group group_id="O1">
            <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 mg/Lira 3.0 mg</title>
            <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O4">
            <title>Lira 2.4 mg/Lira 3.0 mg</title>
            <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 3.0 mg</title>
            <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
          </group>
          <group group_id="O6">
            <title>Orlistat</title>
            <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure at Week 104</title>
          <description>Calculated as mean blood pressure at week 104-baseline.</description>
          <population>ITT (intention to treat) analysis set using (LOCF) last observation carried forward is all randomised and exposed subjects from the double-blind period, who have been exposed to at least one dose of trial product</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Systolic )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.6" spread="11.1"/>
                    <measurement group_id="O2" value="127.2" spread="13.1"/>
                    <measurement group_id="O3" value="123.4" spread="13.0"/>
                    <measurement group_id="O4" value="126.3" spread="13.9"/>
                    <measurement group_id="O5" value="124.3" spread="11.3"/>
                    <measurement group_id="O6" value="122.7" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104 (Systolic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="13.8"/>
                    <measurement group_id="O2" value="-4.0" spread="13.4"/>
                    <measurement group_id="O3" value="-3.8" spread="16.0"/>
                    <measurement group_id="O4" value="-6.5" spread="12.6"/>
                    <measurement group_id="O5" value="-5.6" spread="11.7"/>
                    <measurement group_id="O6" value="-2.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Diastolic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.78" spread="8.50"/>
                    <measurement group_id="O2" value="79.71" spread="9.12"/>
                    <measurement group_id="O3" value="77.91" spread="7.92"/>
                    <measurement group_id="O4" value="78.53" spread="8.23"/>
                    <measurement group_id="O5" value="77.84" spread="8.38"/>
                    <measurement group_id="O6" value="76.94" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104 (Diastolic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="8.47"/>
                    <measurement group_id="O2" value="-0.98" spread="9.81"/>
                    <measurement group_id="O3" value="-1.00" spread="9.37"/>
                    <measurement group_id="O4" value="-1.99" spread="9.61"/>
                    <measurement group_id="O5" value="-1.92" spread="9.41"/>
                    <measurement group_id="O6" value="-1.11" spread="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were collected over 104 weeks.</time_frame>
      <desc>Safety analysis set consists of all subjects exposed to trial product(s).</desc>
      <group_list>
        <group group_id="E1">
          <title>Lira Placebo/Lira 2.4 mg/Lira 3.0 mg</title>
          <description>Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="E2">
          <title>Lira 1.2 mg/Lira 3.0 mg</title>
          <description>Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="E3">
          <title>Lira 1.8 mg/Lira 3.0 mg</title>
          <description>Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="E4">
          <title>Lira 2.4 mg/Lira 3.0 mg</title>
          <description>Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="E5">
          <title>Liraglutide 3.0 mg</title>
          <description>Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)</description>
        </group>
        <group group_id="E6">
          <title>Orlistat</title>
          <description>Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroglossal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaesthetic complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Ligament calcification</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="90" subjects_at_risk="93"/>
                <counts group_id="E6" subjects_affected="89" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="10" subjects_affected="7" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E5" events="9" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E6" events="10" subjects_affected="8" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="95"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="90"/>
                <counts group_id="E4" events="29" subjects_affected="22" subjects_at_risk="93"/>
                <counts group_id="E5" events="23" subjects_affected="19" subjects_at_risk="93"/>
                <counts group_id="E6" events="9" subjects_affected="7" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="98"/>
                <counts group_id="E2" events="23" subjects_affected="15" subjects_at_risk="95"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="90"/>
                <counts group_id="E4" events="20" subjects_affected="18" subjects_at_risk="93"/>
                <counts group_id="E5" events="21" subjects_affected="18" subjects_at_risk="93"/>
                <counts group_id="E6" events="49" subjects_affected="33" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="95"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E4" events="19" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="13" subjects_affected="12" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="29" subjects_at_risk="98"/>
                <counts group_id="E2" events="47" subjects_affected="35" subjects_at_risk="95"/>
                <counts group_id="E3" events="40" subjects_affected="34" subjects_at_risk="90"/>
                <counts group_id="E4" events="61" subjects_affected="39" subjects_at_risk="93"/>
                <counts group_id="E5" events="76" subjects_affected="47" subjects_at_risk="93"/>
                <counts group_id="E6" events="9" subjects_affected="8" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Steatorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="95"/>
                <counts group_id="E3" events="24" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E4" events="20" subjects_affected="16" subjects_at_risk="93"/>
                <counts group_id="E5" events="16" subjects_affected="13" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="98"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="95"/>
                <counts group_id="E3" events="31" subjects_affected="20" subjects_at_risk="90"/>
                <counts group_id="E4" events="19" subjects_affected="15" subjects_at_risk="93"/>
                <counts group_id="E5" events="26" subjects_affected="21" subjects_at_risk="93"/>
                <counts group_id="E6" events="24" subjects_affected="20" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E2" events="37" subjects_affected="24" subjects_at_risk="95"/>
                <counts group_id="E3" events="17" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E4" events="23" subjects_affected="17" subjects_at_risk="93"/>
                <counts group_id="E5" events="39" subjects_affected="22" subjects_at_risk="93"/>
                <counts group_id="E6" events="39" subjects_affected="25" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="85" subjects_affected="41" subjects_at_risk="98"/>
                <counts group_id="E2" events="69" subjects_affected="37" subjects_at_risk="95"/>
                <counts group_id="E3" events="71" subjects_affected="34" subjects_at_risk="90"/>
                <counts group_id="E4" events="80" subjects_affected="42" subjects_at_risk="93"/>
                <counts group_id="E5" events="74" subjects_affected="38" subjects_at_risk="93"/>
                <counts group_id="E6" events="46" subjects_affected="26" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E4" events="11" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E5" events="10" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="95"/>
                <counts group_id="E3" events="16" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="93"/>
                <counts group_id="E5" events="20" subjects_affected="13" subjects_at_risk="93"/>
                <counts group_id="E6" events="16" subjects_affected="13" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood insulin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Blood TSH increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="98"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E6" events="9" subjects_affected="7" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="98"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="95"/>
                <counts group_id="E3" events="20" subjects_affected="16" subjects_at_risk="90"/>
                <counts group_id="E4" events="17" subjects_affected="16" subjects_at_risk="93"/>
                <counts group_id="E5" events="18" subjects_affected="12" subjects_at_risk="93"/>
                <counts group_id="E6" events="21" subjects_affected="16" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="98"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="37" subjects_affected="23" subjects_at_risk="98"/>
                <counts group_id="E2" events="41" subjects_affected="23" subjects_at_risk="95"/>
                <counts group_id="E3" events="23" subjects_affected="16" subjects_at_risk="90"/>
                <counts group_id="E4" events="54" subjects_affected="23" subjects_at_risk="93"/>
                <counts group_id="E5" events="25" subjects_affected="22" subjects_at_risk="93"/>
                <counts group_id="E6" events="26" subjects_affected="16" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk acknowledges the Investigator’s right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk’s Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

